Hydrogen-rich water supplementation attenuates oxidative stress and inflammation in chronic high-altitude disease patients: A double-blind randomized placebo-controlled study.
Qian Zhang, Fengying Zhang, Yang Zhong, Qiuyue Li, Doudou Hao, Zhiyou Shi, Suying Zhu, Yunhong Wu, Xiaonan Yue · Food research international (Ottawa, Ont.) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In with CHAD were recruited and assigned to the HRW or placebo water (PW) group for 60 days, these results suggest the potential protective role of HRW in CHAD, providing a novel adjuvant therapy for CHAD. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in with CHAD were recruited and assigned to the HRW or placebo water (PW) group for 60 days. These results suggest the potential protective role of HRW in CHAD, providing a novel adjuvant therapy for CHAD.
What the Researchers Studied
The researchers studied with CHAD were recruited and assigned to the HRW or placebo water (PW) group for 60 days. The study used a randomized, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
These results suggest the potential protective role of HRW in CHAD, providing a novel adjuvant therapy for CHAD. Hydrogen-rich water (HRW) is a novel functional food with demonstrated antioxidant and anti-inflammatory properties.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was with CHAD were recruited and assigned to the HRW or placebo water (PW) group for 60 days. The reported sample size was 50. The study used a randomized, placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.